Skip to main content

Table 2 Physical and 2DE structural and functional parameters at baseline

From: The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats

  Level Parameter Group
Control Empagliflozin
   Body weight [gr] 413 ± 35 395 ± 37
Apical level Systolic LVESA [mm2] 16.4 ± 5.9 15.8 ± 5.3
LVIDs [mm] 4.2 ± 0.7 4.6 ± 0.7
Diastolic LVEDA [mm2] 43.3 ± 4.9 39.2 ± 5.4
LVIDd [mm] 7.6 ± 0.6 7.0 ± 0.6
Function FS [%] 39.7 ± 3.9 35.6 ± 3.8
FAC [%] 63.1 ± 3.7 59.0 ± 3.7
EF [%] 74.5 ± 6.4 70.4 ± 6.2
Papillary muscles level Systolic LVESA [mm2] 20.5 ± 4.3 26.2 ± 4.3
LVIDs [mm] 4.3 ± 0.6 4.9 ± 0.7
Diastolic LVEDA [mm2] 51.2 ± 4.7 47.1 ± 4.6
LVIDd [mm] 7.5 ± 0.6 7.3 ± 0.5
Function FS [%] 36.2 ± 3.1 39.7 ± 3.2
FAC [%] 52.3 ± 3.6 56.2 ± 4.0
EF [%] 69.9 ± 5.3 76.4 ± 5.4
  1. LVESA, LVEDA—LV end systolic and end diastolic area, respectively. LVIDs, LVIDd—LV end systolic and end diastolic internal diameter, respectively. FS fractional shortening, FAC fractional area change, EF ejection fraction
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840